Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 7Sarcoma 6Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3Liposarcoma, Myxoid 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Neurofibrosarcoma 2Melanoma 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Carcinoma, Intraductal, Noninfiltrating 2Advanced Refractory Solid Tumors 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thymoma 1Small Cell Lung Cancer Limited Stage 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myosarcoma 1Lymphatic Metastasis 1Lymphangiosarcoma 1Locally Recurrent Rectal Cancer 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × Radiation Dose Hypofractionation × Clear all
NCT04310020 2026-05-13

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

National Cancer Institute (NCI)

Phase 2 Active not recruiting
47 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Zhejiang Cancer Hospital

Phase 2 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00983307 2025-04-30

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

Thomas Jefferson University

Phase 2 Completed
17 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03050060 2022-06-22

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

University of Washington

Phase 2 Terminated
21 enrolled 12 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02947113 2017-11-30

HYPOLAN

The Netherlands Cancer Institute

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡